CDK4/6 inhibition triggers anti-tumour immunity-Reference-Cited by-同舟云学术

CDK4/6 inhibition triggers anti-tumour immunity

Published:2017-08 Issue:7668 Volume:548 Page:471-475
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Goel Shom,DeCristo Molly J.,Watt April C.,BrinJones Haley,Sceneay Jaclyn,Li Ben B.,Khan Naveed,Ubellacker Jessalyn M.,Xie Shaozhen,Metzger-Filho Otto,Hoog Jeremy,Ellis Matthew J.,Ma Cynthia X.,Ramm Susanne,Krop Ian E.,Winer Eric P.,Roberts Thomas M.,Kim Hye-Jung,McAllister Sandra S.,Zhao Jean J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature23465.pdf

Reference30 articles.

1. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23–32 (2006)

2. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438–451 (2012)

3. Patnaik, A. et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6, 740–753 (2016)

4. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016)

5. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512 (1999)

Cited by 1047 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer;International Immunopharmacology;2024-12

2. Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors;Molecular Oncology;2024-09-11

3. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer;Cancer Research Communications;2024-09-01

4. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases;International Immunopharmacology;2024-09

5. Targeting transposable elements in cancer: developments and opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09